Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status

Overview of attention for article published in Clinical and Translational Oncology, June 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

twitter: 5 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 24 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 14,398 followers.

#PubSaludMurcia Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status. https://t.co/JI9oxyTDFx

21 Mar 2020

Reply Repost Favourite

RT @BibliotecaHUCA: PubMed- https://t.co/Oz8CYjLkrj Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinica…

21 Mar 2020

Reply Repost Favourite

RT @BibliotecaHUCA: PubMed- https://t.co/Oz8CYjLkrj Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinica…

20 Mar 2020

Reply Repost Favourite

PubMed- https://t.co/Oz8CYjLkrj Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status. @HUCA_Asturias #publiHUCA @PaulaJFonseca #MedicalOncology @

20 Mar 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.